Evidence map›Paper›PMID 42683750›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Matrix-Activated Aptamer Sensors for Human Serum Analysis.

Amandine Barbaroux, Benoit Chovelon, Emmanuelle Fiore, Sebastien Vezirian, Mickael Henry, Marwa Zoubeidi, Maria C DeRosa, Corinne Ravelet, Eric Peyrin

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amandine BarbarouxDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.ORCID https://orcid.org/0009-0009-7898-2677
Benoit ChovelonDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.
Emmanuelle FioreDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.
Sebastien VezirianDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.
Mickael HenryDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.
Marwa ZoubeidiDepartment of Chemistry, Carleton University, Ottawa, Canada.
Maria C DeRosaDepartment of Chemistry, Carleton University, Ottawa, Canada.ORCID https://orcid.org/0000-0003-1868-6357
Corinne RaveletDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.
Eric PeyrinDPM UMR 5063, University Grenoble Alpes - CNRS, Grenoble, France.ORCID https://orcid.org/0000-0001-5558-6369

Funding

Labex Arcane and CBH-EUR-GS (ANR-17-EURE-0003)Labex CERCOG@UGA (ANR-15-IDEX-0002)Polynat Carnot Institute (ANR-11-CARN-007-01)
6 · The paper itself

Abstract

Owing to their ease of operation, solution-phase fluorescent sensors hold a crucial position among aptamer-based detection tools. However, their performance is regularly compromised when exposed to increasing levels of blood fluids, such as human serum, which limits their potential in clinical settings. Here, we introduce a sensing platform that behaves advantageously within this biological medium, leveraging the most abundant proteins in the matrix, namely albumin and immunoglobulin G, as endogenous activators of fluorophore-labeled aptamers. In the absence of a target, these serum proteins non-specifically assemble with the aptamer probe in situ. Upon target binding, the aptamer-protein complexes are disrupted, shifting the equilibria toward the probe unbound to biopolymers. The fluorescence anisotropy readout reveals the system's reactivity to small-molecule targets, offering the unique ability to provide both enhanced and consistent responses across a range of high serum levels (25%-90%). As the sensor's performance may be sensitive to inter-sample serum variations, a standard addition calibration approach is used to ensure reliable quantitative analyses. Overall, the proposed strategy addresses substantial serum-induced perturbations and preserves assay functionality under biologically challenging conditions, thereby establishing a practical framework for extending homogeneous aptamer-based sensing to clinically relevant blood matrices.

Indexed as

Aptamers, NucleotideBiosensing TechniquesImmunoglobulin GSerum AlbuminFluorescent DyesHumansAptamers, NucleotideFluorescent DyesImmunoglobulin GSerum Albuminaptamerfluorescent sensorhuman serummatrix proteinssmall‐molecule

Identifiers

PMID42683750
PMCPMC13653630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.